Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Q1 2024 Earnings Call Transcript
Neurocrine Biosciences, Inc. misses on earnings expectations. Reported EPS is $0.4189 EPS, expectations were $1.04. Neurocrine Biosciences, Inc.
Neurocrine Biosciences Inc (NBIX)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Rock Springs Capital Management Kris Jenner, Gordon Bussard, Graham Mcphail | 1,054,900 | $145,491,808 | -12% | 3.69% |
| 2. | Armistice Capital Steven Boyd | 1,023,739 | $141,194,083 | -3% | 1.87% |
| 3. | AQR Capital Management Cliff Asness | 994,611 | $137,176,750 | +35% | 0.23% |
| 4. | Citadel Investment Group Ken Griffin | 841,318 | $116,034,579 | +652% | 0.02% |
| 5. | Point72 Asset Management Steve Cohen | 837,426 | $115,497,794 | -40% | 0.27% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $5.96 | 22,300 | Large Shareholder | 3,527,700 | 2011-10-12 | Filing | |
| $5.96 | 1,000 | Large Shareholder | 757,600 | 2011-10-12 | Filing | |
| $5.96 | 6,200 | Large Shareholder | 1,236,665 | 2011-10-12 | Filing | |
| $5.73 | 3,800 | Large Shareholder | 3,505,400 | 2011-10-11 | Filing | |
| $5.59 | 44,700 | Large Shareholder | 3,501,600 | 2011-10-10 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $150.04 | 900 | Officer | 18,202 | 2024-07-16 | Filing | |
| $150.04 | 900 | Officer | 6,607 | 2024-07-16 | Filing | |
| $150.00 | 1,557 | Officer | 7,507 | 2024-07-16 | Filing | |
| $150.10 | 400 | Officer | 7,507 | 2024-07-16 | Filing | |
| $150.03 | 930 | Director | 119,047 | 2024-07-16 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 13,647,891 | $1,798,246,116 | 0.04% | |
| 2. | 9,710,328 | $1,279,432,817 | 0.02% | |
| 3. | 4,063,336 | $535,385,151 | 0.02% | |
| 4. | 2,430,500 | $320,242,680 | 4.89% | |
| 5. | 2,326,294 | $306,512,662 | 0.02% |
News See All
Insiders Are Dumping These 5 Healthcare Stocks
Crinetics Pharmaceuticals Inc (NASDAQ:CRNX) is a clinical stage biopharma company that is working on treatments for endocrine-related diseases.
5 Best Small-Cap Growth Stocks to Invest In
In this piece, we will take a look at the five best small-cap growth stocks to invest in.
Wall Street Analysts Just Trimmed Price Targets for These 10 Stocks
In this article, we will discuss the 10 stocks whose price targets were recently trimmed by analysts.
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Q4 2023 Earnings Call Transcript
Operator: Good day and welcome to Neurocrine Biosciences’ year-end and fourth quarter results call. At this time, all participants are in a listen-only mode.
Growth Stock Portfolio: 15 Companies with At Least 30% Annual Growth Rates
In this article, we will take a look at the 15 stocks with at least 30% annual growth rates to consider for a growth stock portfolio.
5 High Growth NASDAQ Stocks That Are Profitable
This article presents an overview of the 5 High Growth NASDAQ Stocks That Are Profitable. For a detailed overview of such stocks, read our article, 14 High Growth NASDAQ Stocks That Are Profitable...
5 High Growth Non-Tech Stocks That Are Profitable
This article presents an overview of the 5 High Growth Non-Tech Stocks That Are Profitable. For a detailed overview of such stocks, read our article, 17 High Growth Non-Tech Stocks That Are Profitable...
13 High Growth Healthcare Stocks to Buy
In this article, we will take a look at 13 high growth healthcare stocks to buy.
Here’s Why Neurocrine Biosciences (NBIX) Rose in Q3
Harding Loevner, an asset management company, released its “Global Small Companies Equity Strategy” third-quarter 2023 investor letter. A copy of the same can be downloaded here.
Billionaire Hedge Funds
